Inheart, a Pessac, France-based medical device company, raised USD11M in funding.
The round was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In addition, inheart received funds from a crowdequity campaign on Tudigo and from the UK impact fund Astorg Foundation.
The company intends to use the funds to support the commercial expansion of its digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum.
Led by CEO Todor Jeliaskov, inheart is delivering an AI-driven, digital twin of the heart to advance the care of patients living with cardiac disease. It is committed to addressing the needs of the cardiac care continuum by providing personalized therapy in a predictive manner for screening and early detection of cardiac diseases.
Commenting on the news, Todor Jeliaskov said: “This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.”
FinSMEs
07/05/2024